Value of the European Organization for Research and Treatment of Cancer risk tables in predicting recurrence and progression for non-muscle invasive bladder cancer in Chinese patients
10.3760/cma.j.issn.1000-6702.2011.04.005
- VernacularTitle:欧洲癌症研究与治疗组织风险评分表对国人非肌层浸润性膀胱癌预后判断的意义
- Author:
Shuo LIU
;
Guang SUN
;
Wenlong MIAO
;
Fengqi LI
;
Zhe WANG
- Publication Type:Journal Article
- Keywords:
Urinary bladder neoplasms;
Carcinoma;
Non muscle-invasive bladder cancer;
European Organization for Research and Treatment of Cancer risk tables;
Prognosis
- From:
Chinese Journal of Urology
2011;32(4):232-235
- CountryChina
- Language:Chinese
-
Abstract:
Objective To Validate the prognostic significance of the European Organization for Research and Treatment of Cancer (EORTC) risk tables in Chinese patients with non-muscle invasive bladder cancer (NMIBC). Methods According to the scoring standard of the EORTC system, 225 NMIBC patients were reviewed and divided into 3 groups: low, intermediate and high risk groups for recurrence and progression respectively. The probabilities of recurrence and progression at 1 year and 5 year for each group were calculated using life-table analysis and then compared with the EORTC risk tables. Log-Rank test and multivariable analysis were used to analyze the possible differences between risk groups and to find independent prognostic factors. Results For low (n= 32, 25), intermediate (n=109, 128) and high (n=84, 72) risk groups, the probabilities of recurrence and progression at 1 year were 15. 1%, 31.2%, 55.5% and 0. 3%, 2. 0%, 15.5% respectively. The probabilities at 5 year were 28. 2%, 55.2%, 75.0% and 1.4%, 12.9%, 54. 7%. All the results were similar to that of EORTC tables except the probability of progression at 5 year for the high progression risk group.The differences between different risk groups were significant (P＜0.01). In a multivariable analysis for recurrence and progression, the EORTC scores had independent significance (P＜0.01). Conclusions EORTC risk tables could stratify NMIBC patients effectively according to the risk of recurrence and progression. It could be a useful tool for Chinese urologists.
